Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2023.2173253
Abstract: Abstract Context Poziotinib and vonoprazan are two drugs mainly metabolized by CYP3A4. However, the drug-drug interaction between them is unknown. Objective To study the interaction mechanism and pharmacokinetics of poziotinib on vonoprazan. Materials and methods… read more here.
Keywords: poziotinib; vonoprazan; drug drug; drug interaction ... See more keywords
Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-21-3106
Abstract: Evaluation of the functional impact of HER2 mutations on therapy-induced resistance and metastasis identifies robust antitumor activity of poziotinib and supports the clinical evaluation of poziotinib in ER+ HER2 mutant breast cancer. read more here.
Keywords: metastasis; her2 mutant; poziotinib; breast cancer ... See more keywords
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps9106
Abstract: TPS9106Background: Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the EGFR family of tyrosine-kinase receptors, including human epiderma... read more here.
Keywords: poziotinib patients; poziotinib; egfr her2; phase study ... See more keywords